Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22250189 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions: Drug: O6-benzylguanine;   Drug: carmustine;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years